To explore additional potential therapeutic targets and facilitate comprehensive treatment decisions, we analyzed actionable mutation profiles in patients with NRG1 fusions across lung cancer, colorectal cancer, and breast cancer. This evidence concerns the gene NRG1 and breast cancer.